Scholarlink

<p>Radiation-induced xerostomia is a significant concern for patients undergoing radiotherapy for head and neck cancer. This study aimed to evaluate the effect of radiation dose to the parotid gland on the severity of xerostomia using the Multidisciplinary Salivary Gland Society (MSGS) questionnaire administered 6 months post-radiotherapy. The study included 36 patients who received radiotherapy for various head and neck malignancies. They were stratified based on mean parotid radiation doses: less than 15&#xa0;Gy,16–25&#xa0;Gy and more than 26&#xa0;Gy. All patients who met the eligibility criteria were evaluated for xerostomia using the Novel Multidisciplinary Salivary Gland Society (MSGS) questionnaire 6 months post radiotherapy. Results indicated that lower radiation doses corresponded to milder symptoms of dry mouth, whereas higher doses correlated with more pronounced xerostomia. (p value − 0.0466). Mean Xerostomia scores were 44.2,66.38 and 85.4 for the subgroups receiving mean parotid radiation dose of less than 15&#xa0;Gy,16–25&#xa0;Gy and more than 26&#xa0;Gy respectively. These findings highlight the critical role of radiation dose optimization in mitigating xerostomia and improving post-treatment quality of life for head and neck cancer patients. Future research should explore personalized radiation strategies to further minimize salivary gland damage and enhance patient outcomes.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Radiation Dose Effects on Salivary Gland Function in Head and Neck cancer patients- A Prospective Study

  • 期刊论文

  • 发表日期：

    2025年6月23日

查看全文
  • Apoorva K V,
  • Vijendra Shenoy S,
  • Rabia Suzanne Angiras,
  • Athiyamaan M S,
  • Pooja Varshini Raja,
  • Kshithi Kudlu,
  • Rahul K,
  • Ananya Sinha

摘要

Radiation-induced xerostomia is a significant concern for patients undergoing radiotherapy for head and neck cancer. This study aimed to evaluate the effect of radiation dose to the parotid gland on the severity of xerostomia using the Multidisciplinary Salivary Gland Society (MSGS) questionnaire administered 6 months post-radiotherapy. The study included 36 patients who received radiotherapy for various head and neck malignancies. They were stratified based on mean parotid radiation doses: less than 15 Gy,16–25 Gy and more than 26 Gy. All patients who met the eligibility criteria were evaluated for xerostomia using the Novel Multidisciplinary Salivary Gland Society (MSGS) questionnaire 6 months post radiotherapy. Results indicated that lower radiation doses corresponded to milder symptoms of dry mouth, whereas higher doses correlated with more pronounced xerostomia. (p value − 0.0466). Mean Xerostomia scores were 44.2,66.38 and 85.4 for the subgroups receiving mean parotid radiation dose of less than 15 Gy,16–25 Gy and more than 26 Gy respectively. These findings highlight the critical role of radiation dose optimization in mitigating xerostomia and improving post-treatment quality of life for head and neck cancer patients. Future research should explore personalized radiation strategies to further minimize salivary gland damage and enhance patient outcomes.